- |||||||||| tasadenoturev (DNX-2401) / DNAtrix
Trial primary completion date, Oncolytic virus: D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Jun 11, 2015 P1, N=31, Recruiting, Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jun 2014 Trial primary completion date: Mar 2015 --> Dec 2015
- |||||||||| verapamil intralesional / Stada
Enrollment change, Trial termination, Trial primary completion date: Verapamil vs Steroid to Prevent Keloid Recurrence (clinicaltrials.gov) - Jun 11, 2015 P4, N=14, Terminated, Trial primary completion date: Sep 2014 --> Jul 2015 N=30 --> 14 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Mar 2014; Objective of study achieved after interim analysis.
- |||||||||| esmolol / Generic mfg.
Enrollment closed, Trial primary completion date: Postoperative Analgesia Impact of Narcotic Free Anesthesia (clinicaltrials.gov) - May 29, 2015 P=N/A, N=84, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Mar 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2013
- |||||||||| Trial completion: Phone Interview to Prevent Recurring Opioid Overdoses (clinicaltrials.gov) - May 28, 2015
P=N/A, N=30, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2013 Enrolling by invitation --> Completed
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: SCORE: Salvage Cryotherapy in Recurrent Prostate Cancer (clinicaltrials.gov) - May 27, 2015
P=N/A, N=60, Terminated, Enrolling by invitation --> Completed N=800 --> 60 | Recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Jun 2012; Study was ended due to low enrollment
- |||||||||| Enrollment open, Tumor cell: Circulating Tumor Cells in Operative Blood (clinicaltrials.gov) - May 21, 2015
P=N/A, N=20, Recruiting, Active, not recruiting --> Completed | N=10 --> 6 | Trial primary completion date: Dec 2014 --> May 2013 Not yet recruiting --> Recruiting
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Regional Anesthesia and Lung Cancer Recurrence (clinicaltrials.gov) - May 19, 2015
P=N/A, N=67, Terminated, Recruiting --> Completed N=1532 --> 67 | Recruiting --> Terminated | Trial primary completion date: Aug 2013 --> Dec 2015; The principal investigator decided to close this study site.
- |||||||||| chloroquine phosphate / Generic mfg., primaquine / Generic mfg.
Enrollment closed, Trial primary completion date: Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan (clinicaltrials.gov) - Apr 23, 2015 P=N/A, N=50, Active, not recruiting, No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> Sep 2015
- |||||||||| NeuVax (nelipepimut-S) / Dr. Reddy's
Enrollment closed, Trial primary completion date: PRESENT: Efficacy and Safety Study of NeuVax (clinicaltrials.gov) - Apr 15, 2015 P3, N=700, Active, not recruiting, Trial primary completion date: Nov 2015 --> Sep 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Apr 2018
- |||||||||| Trial primary completion date: FACBC for Recurrent Prostate Cancer (clinicaltrials.gov) - Apr 15, 2015
P2, N=25, Recruiting, Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Apr 2018 Trial primary completion date: Mar 2015 --> Sep 2015
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: Cimzia Versus Mesalamine for Crohn's Recurrence (clinicaltrials.gov) - Apr 15, 2015 P4, N=24, Recruiting, Trial primary completion date: Mar 2015 --> Sep 2015 Trial primary completion date: Dec 2014 --> Dec 2016
- |||||||||| Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Enrollment closed: Low-Dose Naltrexone for Depression Relapse and Recurrence (clinicaltrials.gov) - Apr 8, 2015 P2, N=36, Active, not recruiting, Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- |||||||||| midazolam hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: 2-octyl Cyanoacrylate for Closure of Urethrocutaneous Fistula. (clinicaltrials.gov) - Mar 24, 2015 P3, N=42, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Jan 2015
- |||||||||| sorafenib / Generic mfg.
Enrollment change: Sorafenib in Hormone Na (clinicaltrials.gov) - Mar 7, 2015 P2, N=0, Withdrawn, N=44 --> 20 N=60 --> 0
- |||||||||| Enrollment closed: RRR: Reducing Risk of Recurrence (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=150, Active, not recruiting, N=60 --> 0 Recruiting --> Active, not recruiting
|